BRIEF published on 09/18/2024 at 07:05, 1 year 9 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 9 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 10 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 10 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 10 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 11 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 1 year 11 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 2 years ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 2 years ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 07/16/2026 at 15:30, 24 minutes ago Caldwell Announces Leadership Appointments for Industrial Practice and Caldwell Analytics
Published on 07/16/2026 at 15:30, 24 minutes ago Resilient Energy Inc. Advances Commercial Rollout; Operations Enter Final Stage Ahead of Revenue Generation
Published on 07/16/2026 at 14:00, 1 hour 54 minutes ago Stream Hatchet Named a Data Provider for the 2026 Esports World Cup
Published on 07/16/2026 at 13:00, 2 hours 54 minutes ago High Tide Resources Provides Update from its Labrador West Iron Project
Published on 07/16/2026 at 13:00, 2 hours 54 minutes ago NOA Lithium Provides Update on 2026 Exploration Drilling Program At Rio Grande Project
Published on 07/16/2026 at 15:42, 12 minutes ago EQS-Adhoc: Cherry SE successfully completes rights issue
Published on 07/16/2026 at 15:37, 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: Forward Industries Inc.
Published on 07/16/2026 at 15:35, 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 07/16/2026 at 15:34, 20 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 07/16/2026 at 08:45, 7 hours 9 minutes ago Air Liquide invests over 160M USD in the U.S. to supply advanced chips manufacturing in Arizona
Published on 07/15/2026 at 17:45, 22 hours 9 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2026
Published on 07/15/2026 at 17:45, 22 hours 9 minutes ago Half yearly report on the liquidity contract
Published on 07/15/2026 at 17:40, 22 hours 14 minutes ago Report on share repurchases from 8 to 14 July 2026
Published on 07/13/2026 at 18:00, 2 days 21 hours ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
